Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL-COR
2023-505270-15-00Phase 4Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Overweight, obesity and coronary arteriosclerosis comparing Tirzepatide with Placebo (2 arms). Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
Overweightobesitycoronary arteriosclerosis
Beyond the preview
Go deeper on 2023-505270-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505270-15-00.